Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs

Biological and Pharmaceutical Bulletin

Volumn 38, Issue 2, 2015, Pages 155-168

  Maeda, Kazuya ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Drug drug interaction; Genetic polymorphism; Hepatocyte; Organic anion transporting polypeptide

Indexed keywords

ATORVASTATIN; ATRASENTAN; BOSENTAN; CERIVASTATIN; CLARITHROMYCIN; CYCLOSPORIN A; CYTOCHROME P450 3A; FLUINDOSTATIN; GEMFIBROZIL; GLIBENCLAMIDE; INDINAVIR; IRINOTECAN; LOPINAVIR; NATEGLINIDE; ORGANIC ANION TRANSPORTER B; PITAVASTATIN; PRAVASTATIN; REPAGLINIDE; RIFAMPICIN; RIFAMYCIN; ROSUVASTATIN; SIMEPREVIR; SIMVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; TELMISARTAN; TEMOCAPRIL; TORASEMIDE; UNINDEXED DRUG; VALSARTAN;

AREA UNDER THE CURVE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG INHIBITION; DRUG INTERACTION; DRUG SELECTIVITY; DRUG UPTAKE; GENETIC POLYMORPHISM; HUMAN; LIVER CLEARANCE; MAXIMUM REACTION VELOCITY; PHARMACODYNAMICS; PHARMACOGENETICS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW; SLCO1B1 GENE;

EID: 84964199585     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b14-00767     Document Type: Review

References (83)

1. Hagenbuch B, Stieger B. The SLCO (former SLC21) superfamily of transporters. Mol. Aspects Med., 34, 396-412 (2013).
2. König J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem., 275, 23161-23168 (2000).
3. Chu X, Bleasby K, Evers R. Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opin. Drug Metab. Toxicol., 9, 237-252 (2013).
4. Maeda K, Sugiyama Y. Excretion systems. Encyclopedia of Drug Metabolism and Interactions. (Lyubimov A, et al. eds.) Vol. 3, Wiley, New York, pp. 1-32 (2012).
5. Briz O, Serrano MA, MacIas RI, Gonzalez-Gallego J, Marin JJ. Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem. J., 371, 897-905 (2003).
6. Cui Y, Konig J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J. Biol. Chem., 276, 9626-9630 (2001).
7. van de Steeg E, Stranecky V, Hartmannova H, Noskova L, Hrebicek M, Wagenaar E, van Esch A, de Waart DR, Oude Elferink RP, Kenworthy KE, Sticova E, al-Edreesi M, Knisely AS, Kmoch S, Jirsa M, Schinkel AH. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J. Clin. Invest., 122, 519-528 (2012).
8. Maeda K, Sugiyama Y. In vitro - in vivo Scale-up of Drug Transport Activities. Drug Transporters. (You G, Morris M eds.) Wiley, New Jersey, pp. 557-588 (2007).
9. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther., 311, 139-146 (2004).
10. Crespi CL, Penman BW. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv. Pharmacol., 43, 171-188 (1997).
11. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab. Dispos., 34, 1229-1236 (2006).
12. Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab. Dispos., 34, 1247-1254 (2006).
13. Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, Roth W, Igarashi T, Sugiyama Y. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab. Dispos., 34, 1109-1115 (2006).
14. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Sugiyama Y. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther., 73, 147-171 (1997).
15. Chiba M, Ishii Y, Sugiyama Y. Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J., 11, 262-276 (2009).
16. Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci., 27, 425-446 (2006).
17. Maeda K, Sugiyama Y. Prediction of Hepatic Transporter-Mediated Drug-Drug Interaction from In Vitro Data. Transporters in Drug Development. (Sugiyama Y, Steffansen B eds.) Springer, New York, pp. 121-153 (2013).
18. Watanabe T, Maeda K, Kondo T, Nakayama H, Horita S, Kusuhara H, Sugiyama Y. Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments. Drug Metab. Dispos., 37, 1471-1479 (2009).
19. Watanabe T, Kusuhara H, Watanabe T, Debori Y, Maeda K, Kondo T, Nakayama H, Horita S, Ogilvie BW, Parkinson A, Hu Z, Sugiyama Y. Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab. Dispos., 39, 1031-1038 (2011).
20. Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, Sugiyama Y. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab. Dispos., 38, 215-222 (2010).
21. Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y, Yamane N, Kumagai Y, Sugiyama Y. Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin. Pharmacol. Ther., 90, 575-581 (2011).
22. Floyd JS, Kaspera R, Marciante KD, Weiss NS, Heckbert SR, Lumley T, Wiggins KL, Tamraz B, Kwok PY, Totah RA, Psaty BM. A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel. Clin. Pharmacol. Ther., 91, 896-904 (2012).
23. Mück W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S, Johne A, Bauer S, Budde K, Roots I, Neumayer HH, Kuhlmann J. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin. Pharmacol. Ther., 65, 251-261 (1999).
24. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J. Pharmacol. Exp. Ther., 304, 610-616 (2003).
25. Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther., 311, 228-236 (2004).
26. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab. Dispos., 34, 191-197 (2006).
27. Yoshida K, Maeda K, Sugiyama Y. Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms. Annu. Rev. Pharmacol. Toxicol., 53, 581-612 (2013).
28. Food and Drug Administration (FDA). "Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Draft Guidance. US FDA, Silver Spring, MD, U.S.A.": 〈http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm〉, 2012.
29. European Medicines Agency (EMA). "Guideline on the Investigation of Drug Interactions. Final PMP/EWP/560/95, EMA, London.": 〈http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/07/WC500129606.pdf〉, 2012.
30. Pharmaceuticals and Medical Devices Agency (PMDA). Drug interaction guideline for drug development and labeling recommendations (final draft). PMDA, Tokyo (2014).
31. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol. Rev., 50, 387-412 (1998).
32. Ito K, Chiba K, Horikawa M, Ishigami M, Mizuno N, Aoki J, Gotoh Y, Iwatsubo T, Kanamitsu S, Kato M, Kawahara I, Niinuma K, Nishino A, Sato N, Tsukamoto Y, Ueda K, Itoh T, Sugiyama Y. Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS PharmSci, 4, 53-60 (2002).
33. Matsushima S, Maeda K, Ishiguro N, Igarashi T, Sugiyama Y. Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab. Dispos., 36, 663-669 (2008).
34. Yoshida K, Maeda K, Sugiyama Y. Transporter-mediated drug-drug interactions involving OATP substrates: predictions based on in vitro inhibition studies. Clin. Pharmacol. Ther., 91, 1053-1064 (2012).
35. Tachibana T, Kato M, Watanabe T, Mitsui T, Sugiyama Y. Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica, 39, 430-443 (2009).
36. Noé J, Portmann R, Brun ME, Funk C. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab. Dispos., 35, 1308-1314 (2007).
37. Soars MG, Barton P, Ismair M, Jupp R, Riley RJ. The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery. Drug Metab. Dispos., 40, 1641-1648 (2012).
38. Izumi S, Nozaki Y, Komori T, Maeda K, Takenaka O, Kusano K, Yoshimura T, Kusuhara H, Sugiyama Y. Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17beta-glucuronide, estrone-3-sulfate, and sulfobromophthalein. Drug Metab. Dispos., 41, 1859-1866 (2013).
39. Shitara Y, Nagamatsu Y, Wada S, Sugiyama Y, Horie T. Longlasting inhibition of the transporter-mediated hepatic uptake of sulfobromophthalein by cyclosporin a in rats. Drug Metab. Dispos., 37, 1172-1178 (2009).
40. Amundsen R, Christensen H, Zabihyan B, Asberg A. Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic aniontransporting protein 1B1-mediated transport of atorvastatin. Drug Metab. Dispos., 38, 1499-1504 (2010).
41. Gong IY, Kim RB. Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab. Pharmacokinet., 28, 4-18 (2013).
42. Maeda K, Sugiyama Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab. Pharmacokinet., 23, 223-235 (2008).
43. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, Takane H, Irie S, Kusuhara H, Urasaki Y, Urae A, Higuchi S, Otsubo K, Sugiyama Y. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther., 73, 554-565 (2003).
44. Iwai M, Suzuki H, Ieiri I, Otsubo K, Sugiyama Y. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics, 14, 749-757 (2004).
45. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther., 75, 415-421 (2004).
46. Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H, Sugiyama Y. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin. Pharmacol. Ther., 79, 427-439 (2006).
47. Nies AT, Niemi M, Burk O, Winter S, Zanger UM, Stieger B, Schwab M, Schaeffeler E. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med., 5, 1 (2013).
48. Generaux GT, Bonomo FM, Johnson M, Mahar Doan KM. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins. Xenobiotica, 41, 639-651 (2011).
49. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y. Physiologically based pharmacokinetic modeling to predict transportermediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther., 328, 652-662 (2009).
50. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R; SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N. Engl. J. Med., 359, 789-799 (2008).
51. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS. The SLCO1B1∗5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol., 54, 1609-1616 (2009).
52. Donnelly LA, Doney AS, Tavendale R, Lang CC, Pearson ER, Colhoun HM, McCarthy MI, Hattersley AT, Morris AD, Palmer CN. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin. Pharmacol. Ther., 89, 210-216 (2011).
53. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J. Clin. Pharmacol., 48, 311-321 (2008).
54. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivisto KT, Neuvonen PJ. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther., 77, 468-478 (2005).
55. Tomalik-Scharte D, Fuhr U, Hellmich M, Frank D, Doroshyenko O, Jetter A, Stingl JC. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug Metab. Dispos., 39, 927-932 (2011).
56. Vormfelde SV, Toliat MR, Schirmer M, Meineke I, Nurnberg P, Brockmoller J. The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele ∗3 independently affect torsemide pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther., 83, 815-817 (2008).
57. Trdan Lušin T, Stieger B, Marc J, Mrhar A, Trontelj J, Zavratnik A, Ostanek B. Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene. J. Transl. Med., 10, 76 (2012).
58. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos., 33, 434-439 (2005).
59. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Kim HT, Lee JS. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer, 59, 69-75 (2008).
60. Treviño LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, Chan D, Sparreboom A, Giacomini KM, Pui CH, Evans WE, Relling MV. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J. Clin. Oncol., 27, 5972-5978 (2009).
61. Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, Sugiyama Y. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm. Drug Dispos., 34, 45-78 (2013).
62. Letschert K, Keppler D, König J. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics, 14, 441-452 (2004).
63. Picard N, Yee SW, Woillard JB, Lebranchu Y, Le Meur Y, Giacomini KM, Marquet P. The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin. Pharmacol. Ther., 87, 100-108 (2010).
64. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Suzuki T, Habuchi T. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol., 63, 1161-1169 (2007).
65. Chew SC, Sandanaraj E, Singh O, Chen X, Tan EH, Lim WT, Lee EJ, Chowbay B. Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients. Br. J. Clin. Pharmacol., 73, 606-618 (2012).
66. Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci., 99, 967-972 (2008).
67. Yamada A, Maeda K, Ishiguro N, Tsuda Y, Igarashi T, Ebner T, Roth W, Ikushiro S, Sugiyama Y. The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. Pharmacogenet. Genomics, 21, 523-530 (2011).
68. Yamada A, Maeda K, Kiyotani K, Mushiroda T, Nakamura Y, Sugiyama Y. Kinetic Interpretation of the Importance of OATP1B3 and MRP2 in Docetaxel-Induced Hematopoietic Toxicity. CPT Pharmacometrics Syst. Pharmacol., 3, e126 (2014).
69. "Full Prescribing Information for IMBRUVICA™ (ibrutinib).": 〈http://www.janssenmd.com/pdf/imbruvica/PI-Imbruvica.pdf〉.
70. Takashima T, Nagata H, Nakae T, Cui Y, Wada Y, Kitamura S, Doi H, Suzuki M, Maeda K, Kusuhara H, Sugiyama Y, Watanabe Y. Positron emission tomography studies using (15R)-16-m-[11C]tolyl-17,18,19,20-tetranorisocarbacyclin methyl ester for the evaluation of hepatobiliary transport. J. Pharmacol. Exp. Ther., 335, 314-323 (2010).
71. Takashima T, Kitamura S, Wada Y, Tanaka M, Shigihara Y, Ishii H, Ijuin R, Shiomi S, Nakae T, Watanabe Y, Cui Y, Doi H, Suzuki M, Maeda K, Kusuhara H, Sugiyama Y, Watanabe Y. PET imaging-based evaluation of hepatobiliary transport in humans with (15R)-11C-TIC-Me. J. Nucl. Med., 53, 741-748 (2012).
72. Shingaki T, Takashima T, Ijuin R, Zhang X, Onoue T, Katayama Y, Okauchi T, Hayashinaka E, Cui Y, Wada Y, Suzuki M, Maeda K, Kusuhara H, Sugiyama Y, Watanabe Y. Evaluation of Oatp and Mrp2 activities in hepatobiliary excretion using newly developed positron emission tomography tracer [11C]dehydropravastatin in rats. J. Pharmacol. Exp. Ther., 347, 193-202 (2013).
73. He J, Yu Y, Prasad B, Link J, Miyaoka RS, Chen X, Unadkat JD. PET imaging of Oatp-mediated hepatobiliary transport of [(11)C] rosuvastatin in the rat. Mol. Pharm., 11, 2745-2754 (2014).
74. Yoshida K, Maeda K, Kusuhara H, Konagaya A. Estimation of feasible solution space using Cluster Newton Method: application to pharmacokinetic analysis of irinotecan with physiologically-based pharmacokinetic models. BMC Syst. Biol., 7 (Suppl. 3), S3 (2013).
75. Fu Q, Li YP, Gao Y, Yang SH, Lu PQ, Jia M, Zhang LR. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. Eur. J. Clin. Pharmacol., 69, 1269-1274 (2013).
76. Shabana MF, Mishriki AA, Issac MSM, Bakhoum SWG. Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia. Mol. Diagn. Ther., 17, 299-309 (2013).
77. Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lutjohann D, von Bergmann K, Eichelbaum M, Kivisto KT. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin. Pharmacol. Ther., 79, 419-426 (2006).
78. Martin NG, Li KW, Murray H, Putt W, Packard CJ, Humphries SE. The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin. Br. J. Clin. Pharmacol., 73, 303-306 (2012).
79. Hedman M, Antikainen M, Holmberg C, Neuvonen M, Eichelbaum M, Kivisto KT, Neuvonen PJ, Niemi M. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br. J. Clin. Pharmacol., 61, 706-715 (2006).
80. Lee HK, Hu M, Lui S, Ho CS, Wong CK, Tomlinson B. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics, 14, 1283-1294 (2013).
81. Kalliokoski A, Backman JT, Neuvonen PJ, Niemi M. Effects of the SLCO1B1∗1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenet. Genomics, 18, 937-942 (2008).
82. Cheng Y, Wang G, Zhang W, Fan L, Chen Y, Zhou HH. Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers. Eur. J. Clin. Pharmacol., 69, 407-413 (2013).
83. He J, Qiu Z, Li N, Yu Y, Lu Y, Han D, Li T, Zhao D, Sun W, Fang F, Zheng J, Fan H, Chen X. Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers. Eur. J. Clin. Pharmacol., 67, 701-707 (2011).